Allied Corp has signed a manufacturing and distribution agreement with an established European pharmaceutical company: MGC Pharmaceuticals.
"Under the terms of this agreement, MGC will manufacture Allied’s products within their EU GMP (Good Manufacturing Practices) certified factory," the team with the company explains. "This will enable Allied to have their pharma products produced under procedures and methods that meet the high quality standards of EU GMP. In addition to this, through the MGC sales and distribution agreement, Allied will be able to sell their products following the completion of the PHASE I clinical trial. MGC currently has cannabis-based pharmaceutical products for sale in Europe and has demonstrated a proven ability to commercialize cannabis based pharmaceutical products. Commercialization of Allied’s Post-Traumatic Stress Disorder (PTSD) products into the European, South American and North American marketplace is a key piece of Allied’s strategic plan."
“We are excited to be working with MGC Pharma, a company with a proven track record in clinical research, manufacturing and sales of cannabis-based pharmaceuticals. They have clearly demonstrated that they know the track to successfully bring pharma products to the EU market. We look forward to leveraging their technical capabilities to accelerate development and manufacturing of our first pharmaceutical product for PTSD,” said Calum Hughes, CEO of Allied Corp.
“MGC Pharma is aligned with Allied Corp in their quest to create and provide targeted cannabinoid health solutions manufactured to the highest EU GMP standards. This landmark agreement enables us to not only manufacture, but also extend our sales and distribution footprint by helping to bring Allied’s pharma products to the EU market,” said Roby Zomer, Managing Director of MGC Pharma.
For more information:
Allied Corp
allied.health